Humana Inc. (NYSE:HUM) has been assigned a consensus recommendation of “Hold” from the twenty-two brokerages that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $242.37.

HUM has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $256.00 price target on the stock in a research report on Monday, May 8th. Argus raised shares of Humana from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a research report on Friday, June 9th. BidaskClub cut shares of Humana from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Cantor Fitzgerald lifted their price target on shares of Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a research report on Wednesday, April 26th. Finally, Citigroup Inc. assumed coverage on shares of Humana in a research report on Wednesday, June 28th. They set a “buy” rating and a $275.00 price target on the stock.

Shares of Humana (NYSE:HUM) traded up 0.24% during midday trading on Friday, reaching $250.22. 1,257,223 shares of the company traded hands. The stock has a market capitalization of $36.16 billion, a price-to-earnings ratio of 20.58 and a beta of 0.91. Humana has a 12 month low of $163.50 and a 12 month high of $251.80. The company’s 50 day moving average is $237.33 and its 200-day moving average is $221.21.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating analysts’ consensus estimates of $3.08 by $0.41. The firm had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the previous year, the company posted $2.30 earnings per share. Equities research analysts forecast that Humana will post $11.45 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/08/humana-inc-hum-given-consensus-rating-of-buy-by-brokerages-updated-updated-updated.html.

In other Humana news, VP Heidi S. Margulis sold 1,500 shares of the business’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the completion of the sale, the vice president now owns 8,150 shares in the company, valued at $1,890,474. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the sale, the senior vice president now owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The disclosure for this sale can be found here. 0.80% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. OZ Management LP raised its stake in Humana by 4.9% in the second quarter. OZ Management LP now owns 667,478 shares of the insurance provider’s stock valued at $160,608,000 after buying an additional 30,927 shares during the last quarter. Principal Financial Group Inc. raised its stake in Humana by 4.4% in the second quarter. Principal Financial Group Inc. now owns 349,877 shares of the insurance provider’s stock valued at $84,188,000 after buying an additional 14,732 shares during the last quarter. DSAM Partners London Ltd increased its position in shares of Humana by 0.5% in the second quarter. DSAM Partners London Ltd now owns 45,948 shares of the insurance provider’s stock valued at $11,056,000 after buying an additional 207 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in shares of Humana by 4.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 2,095 shares of the insurance provider’s stock valued at $504,000 after buying an additional 92 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Humana by 0.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,697 shares of the insurance provider’s stock valued at $11,236,000 after buying an additional 260 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.